{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salmeterol+50mcg", "query": { "intervention": "Salmeterol 50mcg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Salmeterol+50mcg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T07:55:24.768Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02826343", "title": "New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Xenon129 MRI imaging", "type": "DRUG" }, { "name": "Gadolinium MRI", "type": "DRUG" }, { "name": "Advair (250mcg/50mcg) one puff twice a day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2016-05-01", "completion_date": "2018-06-15", "has_results": false, "last_update_posted_date": "2020-11-04", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02826343" }, { "nct_id": "NCT00115492", "title": "Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Propionate/Salmeterol Combination Product", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 797, "start_date": "2004-12", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 95, "location_summary": "Jasper, Alabama • Mobile, Alabama • Glendale, Arizona + 88 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00115492" }, { "nct_id": "NCT00633217", "title": "Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Propionate/Salmeterol DISKUS 250/50mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 247, "start_date": "2008-03", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2016-12-08", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 16, "location_summary": "Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Lafayette", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Sunset", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00633217" }, { "nct_id": "NCT01324362", "title": "GSK BHR Study (Sont - Second Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "FP 100mcg", "type": "DRUG" }, { "name": "FP 250mcg", "type": "DRUG" }, { "name": "FP 500mcg", "type": "DRUG" }, { "name": "FSC 100/50mcg", "type": "DRUG" }, { "name": "FSC 250/50mcg", "type": "DRUG" }, { "name": "FSC500/50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 446, "start_date": "2003-01", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01324362" }, { "nct_id": "NCT01355991", "title": "Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Spinal Cord Injury" ], "interventions": [ { "name": "Tiotropium", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James J. Peters Veterans Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2011-08", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2015-10-23", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 2, "location_summary": "West Orange, New Jersey • The Bronx, New York", "locations": [ { "city": "West Orange", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01355991" }, { "nct_id": "NCT00984659", "title": "Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone propionate/salmeterol combination product", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 366, "start_date": "2009-10-29", "completion_date": "2010-07-01", "has_results": true, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 39, "location_summary": "Jasper, Alabama • Mobile, Alabama • Los Angeles, California + 35 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00984659" }, { "nct_id": "NCT00296530", "title": "Study Of Patients With Allergic Rhinitis And Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "fluticasone propionate/salmeterol", "type": "DRUG" }, { "name": "fluticasone propionate", "type": "DRUG" }, { "name": "montelukast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 600, "start_date": "2005-09", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 80, "location_summary": "Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more", "locations": [ { "city": "Ozark", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296530" }, { "nct_id": "NCT00358358", "title": "Chronic Obstructive Pulmonary Disease Endpoints Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Propionate/Salmeterol 500/50mcg combination", "type": "DRUG" }, { "name": "Fluticasone Propionate 500mcg", "type": "DRUG" }, { "name": "Salmeterol 50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 163, "start_date": "2006-03", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 4, "location_summary": "Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more", "locations": [ { "city": "Absecon", "state": "New Jersey" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00358358" }, { "nct_id": "NCT00927758", "title": "Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sandoz", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 105, "start_date": "2009-06", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 3, "location_summary": "Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00927758" }, { "nct_id": "NCT01462344", "title": "6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "ADVAIR 100/50mcg", "type": "DRUG" }, { "name": "ADVAIR 250/50mcg", "type": "DRUG" }, { "name": "FLOVENT 100mcg", "type": "DRUG" }, { "name": "FLOVENT 250mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "4 Years to 11 Years" }, "enrollment_count": 6250, "start_date": "2011-11-17", "completion_date": "2015-11-03", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-09-08T07:55:24.768Z", "location_count": 267, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 208 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Scottsboro", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01462344" } ] }